DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a ...
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern ...
EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence ...
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management ...
GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch. Efficiency and security matters more than just ...
GEODIS' David Frouin explains why securing the lane outranks sustainability and why full corridor models are the cold chain trend to watch. Efficiency and security matters more than just ...
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase ...
Swisslog’s Garrett Freeman says 2027 is the year pharma’s onshoring commitments turn into operational capacity, with physical AI and direct-to-patient growth also on his radar.
AI is no longer a future consideration for pharmaceutical supply chain operators, according to Nitin Jayakrishnan, co-founder and CEO of Freehand.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results